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ABSTRACT: Pyrazolopyrimidines with potent antiprolifer-
ative properties were developed by an adaptive strategy that
applies ligand-based design and phenotypic screening
iteratively and is informed by biochemical assays. To drive
development toward speciﬁc oncopathways, compounds were
tested against cancer cells that overexpress, or not, AXL kinase.
Identiﬁed phenotypic hits were found to inhibit oncotargets
AXL, RET, and FLT3. Subsequent optimization generated
antiproliferative lead compounds with unique selectivity proﬁles, including selective AXL inhibitors and a highly potent inhibitor
of FLT3.
■ INTRODUCTION
The R&D costs of new drug development are continuously
increasing, with ﬁgures of $1.4 billion being estimated as the
average out-of-pocket cost to bring a new drug into the
market.1,2 In response to this challenging situation,3 many
medicinal chemistry laboratories are exploring strategies that
prioritize the search for phenotypic hits over target-based
approaches to accelerate the earlier stages of drug discovery.4
Such strategies are particularly well suited to ﬁnd multitargeted
inhibitors against diﬃcult-to-treat malignancies due to the
heterogeneous nature of these cancers.4−6 Using a strategy that
combines ligand-based design of focused compound libraries
and phenotypic screening in an iterative manner, our lab has
recently reported the discovery of novel anticancer kinase
inhibitors with suitable drug-like properties in a fraction of the
time and preclinical R&D costs typically required in the
industry.7,8
The transmembrane protein AXL is a receptor tyrosine
kinase (RTK) that belongs to the TAM (TYRO3, AXL, and
MER) subfamily. The oncogenic role of AXL has come under
the spotlight in recent years due to its correlation with multiple
cancer-promoting processes.9 Incremented AXL signaling is
associated with poor prognosis and drug resistance in both
solid and hematological malignancies.10 This oncogenic eﬀect
can be mediated through AXL overexpression, upregulation of
its ligand GAS6, or by interaction with other RTKs (e.g.,
EFGR, HER2, FLT3),9,11,12 highlighting the relevant and
complex role of AXL in drug resistance to both targeted
therapies and chemotherapy. While several FDA-approved
kinase inhibitors have been found to inhibit AXL activity as a
secondary target,9 the absence of X-ray crystallographic data for
the AXL kinase has limited the development of robust
structure-based drug discovery activities until very recently
(the ﬁrst crystal structure of the AXL kinase domain in complex
with an inhibitor was reported in 201713).
Because of the timely need of making small molecules able to
interfere with AXL oncogenic pathways, we embarked on a
medchem campaign to search for phenotypically active kinase
inhibitors. Inspired by published literature on inhibitors of
MER (a TAM family member),14 we investigated the
development of focused libraries based on a pyrazolo[3,4-
d]pyrimidine scaﬀold featuring an amino group at the C6
position (Figure 1). To drive development toward the
discovery of kinase inhibitors that inhibit AXL signaling, cell
viability assays were performed against two cancer cell lines: a
drug resistant cancer cell line expressing AXL (positive
discriminating cell model) and a cancer cell line that does
not express AXL (negative discriminating cell model). After
two rounds of synthesis and screening, followed by kinase
inhibition proﬁling of selected hits showing preferential activity
against the AXL-expressing cell line, novel phenotypically active
inhibitors of AXL, RET, and FLT3 were discovered. Further
optimization enabled the discovery of several lead compounds
including eSM156, an FLT3 inhibitor with single-digit nM
potency and high antiproliferative activity against acute myeloid
leukemia (AML) cells.
■ RESULTS AND DISCUSSION
Design, Synthesis, and Screening of Compounds 7a−
j. Wang and co-workers14 explored the development of
trisubstituted pyrazolopyrimidines as MER inhibitors based
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on a docking study with the cocrystal structure of MER and
derivative 52.15 Because the TAM family kinases show
remarkable similarities to one another, in addition to MER,
all compounds were tested against AXL and TYRO3.
Exploration at the C6 position with various alkylamino groups
showed that the larger the alkyl, the higher the degree of
selectivity for MER over AXL. Notably, the use of a
methylamino group at that position resulted in a potent
inhibitor exhibiting superior potency for AXL than for MER (1,
Figure 1). This observation served as the starting point of the
ligand-based design explored in this work.
A 10-member library of derivatives of 1 was synthesized
using the synthetic route described in Scheme 1 (see full details
in the Supporting Information). Commercially available 6-
chloro-1H-pyrazolo[3,4-d]pyrimidine, 3, was treated with N-
iodosuccinimide to iodinate the C3 position of the heterocycle
(94% yield) and thus generate an activated position for
Suzuki−Miyaura cross-coupling. The chloro atom at the C6
position of 4 was then substituted via a SNAr with methylamine
in THF to give 5 in moderate yield (55%). On the basis of in-
house investigations7 suggesting that the presence of a
methylene-linked saturated ﬁve-membered ring at the N1
position of pyrazolopyrimidine scaﬀolds enhances kinase
inhibition activity, intermediate 5 was alkylated via reaction
with iodomethylcyclopentane or 3-bromomethyl-1-3-dioxolane
to give 6a,b in moderate yield (41%). 3-Aryl derivatives 7a−j
were prepared via Suzuki coupling in moderate to good yields
(29−72%).
Derivatives 7a−j were then tested against two breast cancer
cell lines: BT474 cells (AXL−), which does not express AXL,
and AXL-overexpressing mouse breast cancer cells (AXL+), a
cell line created in-house which is resistant to the pan-HER
inhibitor sapatinib. AXL+ and AXL− cells were used as a
positive and negative discriminating cell model, respectively,
with the aim to ﬁnd compounds with preferential activity
against AXL+ cells and thereby bias subsequent chemical design
toward the inhibition of AXL-associated oncopathways, without
ruling out that further proteomics diﬀerences between these
cell lines could drive the design toward additional targets.
Reduction of cell proliferation was employed as the primary
screening output, using the pan-RTK inhibitor foretinib (which
is reported to inhibit AXL at 11 nM)9 as a positive control.
EC50 values were calculated using 8-point half-log dose−
response assays (0.03−100 μM) and the results plotted in
Figure 2. The phenotypic screen showed that the majority of
the compounds in this series were more active against AXL+
cells than AXL−, with three compounds, 7f, 7g, and 7h,
displaying EC50 values equal to or lower than 10 μM. The most
potent compound from this series was 7f, which exhibited sub-
μM activity (0.83 μM) against AXL+ cells and a 2-fold potency
increase over the AXL− BT474 cell line (1.64 μM). Notably,
the antiproliferative potency of its close analogue 7g
(containing a dioxolane group instead of a cyclopentane) was
an order of magnitude lower, indicating that the presence of
one or more oxygen atoms in that moiety negatively aﬀects
activity. Because of the high potency of 7f and its promising
Figure 1. Medicinal chemistry campaign based on the cocrystal structure of 52 and MER (PDB 2G1515) performed by Wang and co-workers13 for
the discovery of MER inhibitor UNC569 and the 6-methylaminopyrazolo[3,4-d]pyrimidine scaﬀold explored in this work.
Scheme 1. Four-Step Synthetic Route for the Preparation of Compounds 7a−j from Commercially Available 6-Chloro-1H-
pyrazolo[3,4-d]pyrimidine, 3
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EC50(AXL
−)/EC50(AXL
+) ratio, the 6-(1-piperazinyl)-pyrid-3-
yl group of 7f was chosen as the C3 motif for the preparation of
a second library of pyrazolopyrimidines.
Design, Synthesis, and Screening of Compounds
10a−g. The second library was designed to explore the
incorporation of more complex moieties at the N1 position of
the pyrazolopyrimidine. Because the presence of a methylene-
linked ﬁve-membered ring at that position generated
compounds with high activity and the 1,3-dioxolanylmethyl
group was found to be suboptimal, other heteroaromatic rings
were considered. To the best of our knowledge, the
introduction of substituted triazolylmethyl groups at the N1
position of the scaﬀold studied in this work have not yet been
reported. A substituted 1,2,3-triazole group (Scheme 2) was
thus selected to facilitate the preparation of diﬀerent analogues
by click chemistry, study novel structure−activity relationships
(SAR), and add freedom-to-operate to the chemical space
under exploration. The alkyne handle was introduced by
alkylation of intermediate 5 with propargyl bromide, giving N-
propargyl derivative 8 in 23% yield. Copper-catalyzed azide−
alkyne cycloadditions were carried out with seven diﬀerent
organic azides using copper iodide, sodium ascorbate, and
triethylamine to give 9a−g in good yields (>66%). Palladium-
catalyzed Suzuki cross-coupling of the triazole-containing
derivatives 9a−g with 6-(1-piperazinyl)pyridyl-4-boronic acid
pinacol ester provided ﬁnal compounds 10a−g.
The antiproliferative activity of 10a−g was then tested
against AXL− and AXL+ cells. As shown in Figure 3, the most
potent derivatives of this series were 10a (R = benzyl) and 10d
(R = 2-(methoxycarbonyl)thienyl)), both of which exhibited
superior antiproliferative activity against AXL+ cells. However,
the potency of 10a and 10d was lower than that of the
phenotypic hit 7f. The introduction of aliphatic rings (10b,c) at
the 3′ position of the triazole ring led to a dramatic reduction in
potency. The direct linkage of phenyl rings to the 3′ position of
the triazole (10e−g) did not improve activity over the benzyl-
containing derivative 10a.
To shed light over the pharmacodynamic proﬁle responsible
for the antiproliferative properties of phenotypic hits 7f,g,h and
10a,d, kinase inhibition activities were evaluated against a panel
of 12 protein kinases. The panel, which included the three
members of the TAM family, was selected based on the
selectivity proﬁle frequently found for other AXL inhibitors.9
Kinase inhibition studies were performed by Reaction Biology
Corporation, USA, by measuring 33P incorporation on the
corresponding kinase substrate relative to DMSO. Calculated
half-maximal inhibitory concentration (IC50) values are shown
in Table 1.
The results from the kinase screenings conﬁrmed that the
most potent phenotypic hits from both libraries inhibited AXL
kinase activity at low μM to sub-μM levels. However, much like
many reported AXL inhibitors,9 in most cases the primary
target was not the AXL kinase, with FLT3 and RET being the
most potently inhibited kinases across the screen. Of note, all
the hits showed selectivity over the TAM family members
TYRO3 and MER, proving the importance of using a
methylamino group at the C6 position of the scaﬀold to
achieve subfamily selectivity. In agreement with the cell-based
assays, derivative 7f displayed the greatest activity against AXL,
FLT3, and RET: 0.12, 0.02, and 0.05 μM, respectively.
Arguably, the most interesting hit from this screening was the
3′-benzyltriazolyl derivative 10a, which exhibited the second
highest potency against AXL (0.4 μM) and, importantly, was
the only inhibitor to display superior activity for AXL than for
Figure 2. EC50 values of 7a−j and the positive control foretinib against
AXL− (red) and AXL+ (blue) cells. Cell viability assay: PrestoBlue
reagent at day 5. Error bars: ±SD from n = 2.
Scheme 2. Synthetic Route for the Preparation of Triazole-
Containing Compounds 10a−g from Intermediate 5
Figure 3. EC50 values of 10a−g and reference hit 7f against AXL−
(red) and AXL+ (blue) cells. Cell viability assay: PrestoBlue reagent at
day 5. Error bars: ±SD from n = 2.
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FLT3 and RET. This preferential selectivity against AXL was
not observed with the close derivative 10d, suggesting that the
ﬂexible benzyl group provides a certain degree of conforma-
tional freedom that is advantageous for binding to the AXL
protein but less favorable for FLT3 and RET.
Design, Synthesis, and Screening of Compounds
12a−f. On the basis of the cell assays and the kinase screening,
six new derivatives of 10a were prepared to search for improved
AXL inhibition. 12a−f were prepared in moderate yields (27−
58%) by Suzuki cross-coupling of intermediate 9a with six
diﬀerent arylboronate/boronic acids. The diversity of the
moieties incorporated at the C3 position (Figure 4) aimed to
evaluate the importance of the H-donor and acceptors of the 6-
(1-piperazinyl)-pyrid-3-yl moiety of 10a.
Following the protocol described above, 12a−f were tested
against AXL− and AXL+ cells and the resulting EC50 values
plotted in Figure 5. Whereas none of the new analogues
improved the activity of 10a against the AXL+ cell line, 12b
showed a superior EC50(AXL
−)/EC50(AXL
+) ratio, potentially
indicating enhanced AXL selectivity. Interestingly, the seemly
minor substitution of the pyridine N atom by a CH led to an
inversion of the cell activity ratio, pointing out oﬀ-target eﬀects.
It was also noticeable that the attachment of large groups at the
piperazinyl NH (12c,d) reduced antiproliferative activity
against the AXL+ cell line. The substitution of the pyperazinyl
group by methylamino (12f) resulted in a completely inactive
derivative.
To understand how these structural changes had aﬀected the
kinase selectivity of the new compounds, 12a−d were screened
against the 12-member panel of kinases used for previous hits.
As before, kinase inhibition screenings were performed using
radioisotope based methods by Reaction Biology Corporation.
Inhibitor BGB324, which is widely considered a selective AXL
inhibitor (even if the available kinase selectivity information is
limited)9 and the ﬁrst one to enter clinical trials based on its
AXL inhibitory properties,16 was used as a positive control.
Calculated IC50 values are shown in Table 2.
As shown in Table 2, derivative 12b exhibited superior AXL
inhibition (0.38 μM) and an increased degree of selectivity over
FLT3 and RET in comparison to reference hit 10a. In silico
studies provided preliminary insights into the binding mode of
12b in AXL and RET (see the Supporting Information). It is
important to note that 10a displayed higher antiproliferative
activity against AXL+ cells (Figure 5), which may be caused by
superior cell permeant properties or by unidentiﬁed oﬀ-target
activities. The rest of the compounds of this series were not as
potent as 12b and showed poorer selectivity proﬁles. Derivative
12a, which was previously found to display a EC50(AXL
−)/
EC50(AXL
+) < 1, did not elicit inhibition to any of the kinases
tested in the screen, further proof that its “inversed”
antiproliferative properties are a consequence of targeting
proteins unrelated to AXL-associated oncopathways. Remark-
ably, the screening revealed that the supposedly AXL-selective
Table 1. IC50 Values (in μM) for 7f,g,h and 10a,d against a
Selection of Recombinant Tyrosine Kinases
kinase/hit 7f 7g 7h 10a 10d
AKT >10 >10 >10 >10 >10
Aurora A 0.16 0.66 0.56 1.8 0.79
AXLa 0.12 0.53 1.3 0.40 0.78
KIT 1.1 7.5 >10 >10 >10
MERa 0.64 6.2 8.7 2.3 8.9
MET 2.1 >10 >10 >10 >10
SRC 1.1 0.89 7.2 1.0 >10
FLT3 0.02 0.10 0.25 0.53 0.86
VEGFR2 0.69 4.5 7.5 >10 >10
mTOR >10 >10 >10 >10 >10
RET 0.05 0.16 1.2 0.60 0.43
TYRO3a >10 >10 >10 >10 >10
aMember of TAM subfamily.
Figure 4. Structure, molecular weight (MW), and cLogP of derivatives
12a−f.
Figure 5. EC50 values of 12a−f and reference hit 10a against AXL−
(red) and AXL+ (blue) cells. Cell viability assay: PrestoBlue reagent at
day 5. Error bars: ±SD from n = 2.
Table 2. IC50 Values (in μM) for 12a−d and BGB324 against
a Selection of Recombinant Tyrosine Kinases
kinase/hit 12a 12b 12c 12d BGB324
AKT >10 >10 1.9 >10 >10
Aurora A >10 0.73 >10 0.84 0.026
AXLa >10 0.38 >10 0.76 0.0007
KIT >10 >10 >10 >10 1.0
MERa >10 2.0 >10 5.4 0.015
MET >10 >10 6.3 >10 3.4
SRC >10 8.3 >10 >10 0.037
FLT3 >10 0.70 >10 1.2 0.0009
VEGFR2 >10 7.6 7.7 >10 0.008
mTOR >10 >10 >10 >10 >10
RET >10 0.90 6.2 4.0 0.003
TYRO3a >10 >10 1.9 >10 0.017
aMember of TAM subfamily.
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inhibitor BGB324 actually inhibits both AXL and FLT3 kinases
with equivalent potency. This information, which to our
knowledge is reported herein for the ﬁrst time, further
illustrates the diﬃculty of designing selective AXL inhibitors
due to the structural similarities of the catalytic domains of AXL
and other RTKs (e.g., FLT3 and RET). Furthermore, it
underlines the value of discovering cell-active AXL kinase-
selective inhibitors such as 10a and 12b.
Design, Synthesis, and Screening of Compounds
13a−d. At this point of the campaign, only 7f exhibited sub-
μM antiproliferative activity against the AXL+ breast cancer cell
model. According to the kinase screen (Table 1), 7f inhibited
AXL with high potency (0.12 μM) and displayed even higher
potency against FLT3 and RET (0.02 and 0.05 μM,
respectively). These two RTKs have been strongly linked to
various malignancies. FLT3 is upregulated in acute lympho-
blastic leukemia,17 and the FLT3-ITD mutation is found in 30−
40% of adult AML patients and associated with low survival
rates. Because of its prognostic importance, the WHO
recommends ascertaining the mutational status of FLT3 in
AML patients.18 RET has been linked to numerous cancer
types, including pancreatic,19 breast cancer,20 and AML.21 RET
is associated with metastasis and cancer relapse, being a
predictor of acquired resistance and poor patient prognosis.
Because AXL has also been associated with AML,22 following
the lab’s ethos of evolving development in response to
inhibitors’ properties to accelerate the discovery of lead
compounds,8 the program was steered toward AML.
Four derivatives featuring a cyclopentylmethyl moiety at N1
position (as 7f) were prepared by Suzuki coupling of
intermediate 6a with the corresponding arylboronate/boronic
acids. The substituents at the C3 position of 13b−d (Figure 6)
were the same as the ones previously used for 12b−d (Figure
4). However, because derivative 12a displayed no inhibition of
AXL, FLT3, or RET (see Table 2), a N-methyl derivative of the
4-pyperazinylphenyl group used in 12a was incorporated at C3
on derivative 13a.
The antiproliferative properties of 13a−d were tested against
the AML cell lines MV4-11 (homozygous FLT3/ITD
mutant25) and MOLM-13 (heterozygous for FLT3/ITD
mutation25), using the dual AXL/FLT3 inhibitor BGB324 as
a positive control. As shown in Figure 7, derivatives 13a and
13b displayed sub-μM EC50 values, highlighting the potent
antiproliferative activity of derivative 13a, which displayed in
both cell lines superior potency than BGB324, an inhibitor that
is currently in clinical development for the treatment of AML.23
Given the fairly similar MW and cLogP of derivatives 13a−d
(Figure 6), it was anticipated that the diﬀerent antiproliferative
activity observed for each member of this series were caused by
variations in on-target potency. Biochemical assays were then
performed for 13a−d against the 12 recombinant kinases tested
before. As shown in Table 3, the analogues’ activity against
FLT3 correlated with their antiproliferative activity in AML
cells. Derivative 13a, the most potent inhibitor of the series,
displayed 1.4 nM activity (IC50) against FLT3 and IC50 values
ranging from 6 to 13 nM for Aurora A, RET, and AXL. To
attain a more detailed picture of the selectivity of the best hits,
13a,b and BGB324 were further screened against a selection of
eight kinases commonly inhibited by FLT3 inhibitors: ALK,
Aurora B, DDR1, EGFR, PDGFRa, and FLT3 mutants FLT
ITD and FLT3 835Y. Derivative 13a showed selectivity over
EGFR and PDGFRa, exhibited moderate potency against
Aurora B and DDR1, and high potency against ALK, FLT ITD,
and FLT3 835Y. The same trend was observed for 13b,
although displaying a potency reduction of 4−8-fold relative to
13a. In comparison with the clinical candidate BGB324, the
potent inhibitor 13a displayed 2-fold lower potency against
RET, FLT3, and its mutants and 4-fold superior potency
against Aurora A. However, it exhibited a 20-fold reduction in
activity against AXL. It is important to note that 13a showed
superior potency against MV4-11 and MOLM-13 cells, which
may be due to improved membrane permeant properties or to
the inhibition of other targets such as Aurora A.
Because of the high potency of 13a in vitro and in cells, an
expanded kinome inhibition study was performed (single dose
Figure 6. Structure, MW, and cLogP of derivatives 13a−d.
Figure 7. EC50 values of 13a−d and BGB324 against MV4-11 and
MOLM-13 cells. Cell viability assay: PrestoBlue reagent at day 5. Error
bars: ±SD from n = 2.
Table 3. IC50 Values (in μM) for 13a−d and BGB324 against
a Selection of Recombinant Kinases
kinase/hit 13a 13b 13c 13d BGB324
AKT >10 >10 >10 >10 >10
ALK 0.05 0.19 ND ND 0.53
Aurora A 0.006 0.03 0.28 0.61 0.026
Aurora B 0.1 0.17 ND ND 0.1
AXLa 0.013 0.07 0.26 7.2 0.0007
DDR1 0.035 0.1 ND ND 0.02
EFGR >10 >10 ND ND 3.9
KIT 0.068 0.36 1.8 >10 1.0
MERa 0.092 0.48 2.5 >10 0.015
MET 0.42 3.5 >10 >10 3.4
SRC 0.093 0.8 3.6 >10 0.037
FLT3 0.0014 0.008 0.1 0.3 0.0009
FLT3 ITD 0.011 0.03 ND ND 0.006
FLT3 D835Y 0.004 0.012 ND ND 0.002
PDGFRa 0.37 0.99 ND ND 0.02
VEGFR2 0.066 0.40 1.9 >10 0.008
mTOR >10 >10 >10 >10 >10
RET 0.006 0.06 0.44 >10 0.003
TYRO3a 0.6 3.67 >10 >10 0.017
aMember of TAM subfamily. ND: not determined.
Journal of Medicinal Chemistry Brief Article
DOI: 10.1021/acs.jmedchem.7b01605
J. Med. Chem. 2018, 61, 2104−2110
2108
of 1 μM, in duplicate) against 369 wild-type kinases. Enzymatic
inhibition was compared to DMSO (= 0% inhibition) and
averaged results plotted in a kinome phylogenetic tree with a
65% cutoﬀ value using TREEspot from DiscoveRx (Figure 8;
values listed in Supporting Information, Table 1). The study
gave a S-score of 0.22 and, although not as potent as FLT3,
most hits (>65% inhibition) belonged to the tyrosine kinase
family. Besides FLT3, the tyrosine kinase JAK3 was also
inhibited at levels superior to 98%. This is relevant as JAK3 is a
proto-oncogene associated with diﬀerent leukemias.24 Other
strongly inhibited proteins from diﬀerent families included
ARK5, MAP4K family kinases, LRRK2, MINK1, RSK4, TNIK,
TRKC, and TYK2.
■ CONCLUSIONS
Using an adaptive approach that combines ligand-based design
of small libraries of pyrazolopyrimidines, target-informative
cancer cell assays, and kinase screenings, two selective AXL
inhibitors and a potent FLT3 inhibitor have been developed.
The discovery of cell active AXL inhibitors 10a (eSM119) and
12b (eSM134) is relevant due to the lack of inhibitors that
targets AXL with selectivity over TAM family members MER
and TYRO3 and other RTKs (e.g., RET, FLT3). The merit of
developing these lead compounds is further highlighted by the
ﬁnding that BGB324, the only inhibitor in clinical development
presumed to be selective for AXL,16 is actually a dual AXL/
FLT3 inhibitor. By steering the program toward AML, the
potent FLT3 inhibitor 13a (eSM156) was discovered, which
displays single-digit nM IC50 against FLT3 and its mutants and
low sub-μM EC50 against AML cells. Given its remarkable
biological properties, eSM156 represents an attractive lead for
future optimization against FLT3 and other proteins discovered
in the kinome screening.
■ EXPERIMENTAL SECTION
General. Chemicals were purchased from Fisher, Sigma-Aldrich, or
VWR. Microwave reactions were carried out in a Biotage Initiator.
NMR spectra were recorded at rt on a 500 MHz Bruker Avance III
spectrometer. Chemical shifts are reported in ppm relative to solvent
peak. Analytical TLC was performed on Merck TLC Silica Gel 60
F254 plates and visualized by UV light. Puriﬁcations were performed
by ﬂash chromatography with commercially available silica gel and
solvents. All compounds used in the biological screenings were
determined to be >95% pure by HPLC.
Synthesis of 3-Iodo-N-methyl-1H-pyrazolo[3,4-d]pyrimidin-
6-amine (5). N-Iodosuccinimide (1.9 g) was added to a suspension of
6-chloro-1H-pyrazolo[3,4-d]pyrimidine (1.0 g) in DMF (15 mL) and
microwave-heated at 120 °C for 1 h. H2O (50 mL) and EtOAc (50 mL
× 3) were added, and the organic layers were collected, washed with
H2O (30 mL × 2) and brine (20 mL), dried over anhydrous MgSO4,
and concentrated in vacuo. Flash chromatography (MeOH/DCM 0−
2%) yielded 4 as a yellow solid (1.64 g, 91%). 1H NMR (500 MHz,
DMSO) δ 14.64 (1 H, s, NH), 9.02 (1 H, s, CH). LRMS (+ve) m/z
[M + 1] 281.00. 4 (500 mg) was dissolved in THF (3 mL), added to
CH3NH2 (12 mL), and microwave heated at 150 °C for 1 h. A white
solid precipitated out, dried by vacuum ﬁltration, and washed with
H2O (3 mL × 3) to yield 5 as a beige solid (270 mg, 55%).
1H NMR
(500 MHz, DMSO) δ 12.61 (1 H, s), 8.46 (1 H, s), 7.54 (1 H, s), 2.83
(3 H, d, J = 3.5). 13C NMR (126 MHz, DMSO) δ 162.7, 157.1, 153.9,
134.2, 93.3, 67.5, 28.5. HRMS (ESI +ve) m/z [M + 1] 275.9737.
Synthesis of 1-(Cyclopentylmethyl)-N-methyl-3-[4-(4-meth-
ylpiperazin-1-yl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-6-amine
(13a). 5 (265 mg) in DMF (3 mL) was added NaH (34 mg) and
stirred until gas evolution subsided. (Iodomethyl)cyclopentane (0.182
mL) was added dropwise and the resulting mix microwave-heated for
1.5 h at 150 °C. H2O (50 mL) and EtOAc (50 mL × 3) were added,
and the organic layers were collected, washed with water (30 mL × 2)
and brine (20 mL), dried over anhydrous MgSO4, and concentrated in
vacuo. The crude was puriﬁed by ﬂash chromatography MeOH/DCM
(0−5%) to give 6a as a yellow solid (133 mg, 40%). 1H NMR (500
MHz, DMSO) δ 8.44 (1 H, s, NH), 7.61 (1 H, s), 4.11 (2 H, s), 2.86
(3 H, s), 1.65−1.21 (9 H, m). 13C NMR (126 MHz, DMSO) δ 162.5,
155.8, 154.2, 112.0, 92.3, 50.7, 32.1, 30.1, 28.3, 24.8. HRMS (ESI +ve)
m/z [M + 1] 358.0523. 6a (60 mg), 4-(4-methylpiperazin-1-
yl)phenylboronic acid (76 mg), K2CO3 (34 mg), PPh3 (20%mol),
and Pd(OAc)2 (5%mol) were dissolved in 9:1 dioxane/water (5 mL)
and microwave-heated at 120 °C for 1 h. H2O (50 mL) and EtOAc
(50 mL × 3) were added, and the organic layers were collected,
washed with water (30 mL × 2) and brine (20 mL), dried over
anhydrous MgSO4, and concentrated in vacuo. The crude was puriﬁed
by ﬂash chromatography (MeOH/DCM 0−10%) to yield 13a as a
yellow solid (31 mg, 45%). 1H NMR (500 MHz, CDCl3) δ 8.93 (1 H,
s), 7.83 (2 H, m), 7.04 (2 H, m), 4.25 (2 H, d, J = 7.5,), 3.34 (5 H, m),
3.09 (3 H, d, J = 5.0), 2.65 (6 H, d, J = 6.0), 2.41 (4 H, s), 1.41 (2 H,
d, J = 5.5), 1.28 (3 H, s). 13C NMR (126 MHz, CDCl3) δ 161.4, 156.0,
153.5, 151.3, 143.9, 127.8, 115.9, 54.9, 50.8, 48.5, 46.1, 40.2, 30.3, 28.6,
24.9. HRMS (ESI +ve) m/z [M + 1] 406.2132.
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